主要文件

查看所有文档

B3436

N-(4-Bromophenyl)-3-[[(4-bromophenyl)amino]sulfonyl]benzamide

Name: N-(4-Bromophenyl)-3-[[(4-bromophenyl)amino]sulfonyl]benzamide
Brand: SIGMA

≥98% (HPLC), solid

别名:

C2-8

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₉H₁₄Br₂N₂O₃S

化学文摘社编号:

300670-16-0

分子量:

510.20

NACRES:

NA.77

PubChem Substance ID:

24724418

UNSPSC Code:

12352200

MDL number:

MFCD00355835

Assay:

≥98% (HPLC)

Form:

solid

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

off-white

solubility

DMSO: ~20 mg/mL, H₂O: insoluble

storage temp.

2-8°C

SMILES string

Brc1ccc(NC(=O)c2cccc(c2)S(=O)(=O)Nc3ccc(Br)cc3)cc1

InChI

1S/C19H14Br2N2O3S/c20-14-4-8-16(9-5-14)22-19(24)13-2-1-3-18(12-13)27(25,26)23-17-10-6-15(21)7-11-17/h1-12,23H,(H,22,24)

InChI key

SJJKUNDBFWUAQB-UHFFFAOYSA-N

Biochem/physiol Actions

N-(4-Bromophenyl)-3-[[(4-bromophenyl)amino]sulfonyl] benzamide is the first inhibitor of aggregation of the polyglutamine (polyQ) sequence of the Huntington′s Disease protein (huntingtin).

N-(4-Bromophenyl)-3-[[(4-bromophenyl)amino]sulfonyl]benzamide is the first inhibitor of aggregation of the polyglutamine (polyQ) sequence of the Huntington′s Disease protein (huntingtin); polyQ aggregation is neurotoxic, and inhibitors of aggregation may be therapeutic in HD and other polyQ diseases; C2-8 inhibited aggregation in HD PC12 cells with an IC50 of 50nM; when administered in food, suppressed neurodegeneration in vivo in the Drosophila HD model.

pictograms

GHS07

signalword

Warning

hcodes

H319,H413

pcodes

P273 - P305 + P351 + P338

Hazard Classifications

Aquatic Chronic 4 - Eye Irrit. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

016K4622

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.

Xiaoqian Zhang et al.

Proceedings of the National Academy of Sciences of the United States of America, 102(3), 892-897 (2005-01-12)

Polyglutamine (polyQ) disorders, including Huntington's disease (HD), are caused by expansion of polyQ-encoding repeats within otherwise unrelated gene products. In polyQ diseases, the pathology and death of affected neurons are associated with the accumulation of mutant proteins in insoluble aggregates.

全球贸易项目编号

货号	GTIN
B3436-25MG	04061832269320
B3436-5MG	04061832977102

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持